689P Effects of durvalumab-metformin on head and neck squamous cell carcinoma (HNSCC) as revealed by digital spatial profiling (DSP)

J Riordan,S Awosanya,S Sussman,J.M Johnson,D Whitaker-Menezes,U Martinez-Outschoorn,D Cognetti,A South,A Linnenbach,R Philips,A Luginbuhl,L Harshyne,A Argiris,A Alnemri,J.M Curry,M Tuluc,M Mahoney

doi:10.1016/j.annonc.2022.07.813

689P Effects of durvalumab-metformin on head and neck squamous cell carcinoma (HNSCC) as revealed by digital spatial profiling (DSP)

J Riordan, S Awosanya + Show 15 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.813

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

#Digital Spatial Profiling #Head And Neck Squamous Cell Carcinoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The combination therapy durvalumab (anti PD-L1) plus metformin (oral anti-hyperglycemic) targets multiple facets of the immunosuppressive tumor microenvironment (TME) in HNSCC to promote anti-tumor immunity. Characterization of the TME is crucial for understanding tumor-immune interactions underlying effective therapies.

Full Text